• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:30:38 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAGX alert in real time by email
    SC 13G/A 1 tm216300d1_sc13ga.htm SC 13G/A

     

    CUSIP NO. 47010C40913GPage 1 of 8 Pages

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. 1 – Exit Filing ) *

     

    Jaguar Health, Inc. 

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share 

    (Title of Class of Securities)

     

    47010C409 

    (CUSIP Number)

     

    December 3 , 2020 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨         Rule 13d-1(b)

     

    x        Rule 13d-1(c)

     

    ¨         Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages 

    Page 1 of 8 Pages

     

     

     

     

     

    CUSIP NO. 47010C40913GPage 2 of 8 Pages

     

    1.            Names of Reporting Persons.

     

    Sagard Capital Partners, L.P.

     

    2.            Check the Appropriate Box if a Member of a Group

     

    (a) ¨

     

    (b) ¨

     

    3.            SEC Use Only

     

    4.            Citizenship or Place of Organization

     

     Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED 

    BY EACH REPORTING PERSON WITH:

     

    5.          Sole Voting Power                         0

     

    6.          Shared Voting Power                    1,910,0431

     

    7.          Sole Dispositive Power                 0

     

    8.          Shared Dispositive Power            1,910,0431

     

     

    9.            Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,910,0431

     

    10.         Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ¨

     

    11.          Percent of Class Represented by Amount in Row (9)

     

    2.8%2

     

     

    1 Consists of (i) 1,144,737 shares of voting common stock of the Issuer, par value $0.0001 per share (“Common Stock”) and (ii) shares of Common Stock issuable upon the exercise of a Common Stock Purchase Warrant, which is currently exercisable for 765,306 shares of Common Stock.

     

    2 Based on shares of Common Stock outstanding as of November 6, 2020, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, that was filed by the Issuer with the U.S. Securities and Exchange Commission on November 16, 2020, plus the shares of Common Stock issuable upon the exercise of the Common Stock Purchase Warrant described above.

     

     

     

    CUSIP NO. 47010C40913GPage 3 of 8 Pages

     

    12.         Type of Reporting Person:

     

    PN

     

     

     

    CUSIP NO. 47010C40913GPage 4 of 8 Pages

     

    Names of Reporting Persons.

     

    Sagard Capital Partners GP, Inc.

     

    2.            Check the Appropriate Box if a Member of a Group

    (a) ¨

     

    (b) ¨

     

    3.            SEC Use Only

     

    4.            Citizenship or Place of Organization

     

     Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED 

    BY EACH REPORTING PERSON WITH:

     

    5.           Sole Voting Power                        0

     

    6.           Shared Voting Power                   1,910,0433

     

    7.           Sole Dispositive Power                0

     

    8.           Shared Dispositive Power           1,910,0433

     

     

    9.            Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,910,0433

     

    10.          Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ¨

     

    11.          Percent of Class Represented by Amount in Row (9)

     

    2.8%4

     

    12.         Type of Reporting Person:

     

    CO

     

     

    3 See footnote 1 on first page.

    4 See footnote 2 on first page.

     

     

     

    CUSIP NO. 47010C40913GPage 5 of 8 Pages

     

    Names of Reporting Persons.

     

    Sagard Capital Partners Management Corp.

     

    2.           Check the Appropriate Box if a Member of a Group

     

    (a) ¨

     

    (b) ¨

     

    3.            SEC Use Only

     

    4.            Citizenship or Place of Organization

     

     Delaware

     

    NUMBER OF SHARES BENEFICIALLY OWNED 

    BY EACH REPORTING PERSON WITH:

     

    5.          Sole Voting Power                         0

     

    6.          Shared Voting Power                    1,910,0435

     

    7.          Sole Dispositive Power                 0

     

    8.          Shared Dispositive Power            1,910,0435.

     

     

    9.            Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,910,0435

     

    10.          Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ¨

     

    11.          Percent of Class Represented by Amount in Row (9)

     

    2.8%6

     

    12.         Type of Reporting Person:

     

    CO

     

     

    5 See footnote 1 on first page.

    6 See footnote 2 on first page.

     

     

     

    CUSIP NO. 47010C40913GPage 6 of 8 Pages

     

    Item 1(a).Name of Issuer:

     

    Jaguar Health, Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    200 Pine Street, Suite 400 

    San Francisco, CA 94104

     

    Item 2(a).Name of Persons Filing:

     

    This Amendment No. 1 (“Amendment”), filed on behalf of Sagard Capital Partners, L.P., a Delaware limited partnership (“Sagard”), Sagard Capital Partners GP, Inc., a Delaware corporation (“GP”), and Sagard Capital Partners Management Corp., a Delaware corporation (“Manager,” and together with Sagard and GP, the “Reporting Persons”), amends and supplements the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on September 11, 2020 (the “Schedule 13G”).

     

    Sagard is the direct owner of the securities of the Issuer reported herein as beneficially owned by each of the Reporting Persons. GP is the general partner of Sagard and Manager is the investment manager of Sagard.

     

    As a result of direct and indirect securities holdings, Power Corporation of Canada (“PCC”) and the Desmarais Family Residuary Trust (the “Trust”), which was created on October 8, 2013 under the Last Will and Testament of Paul G. Desmarais, the trustees of which are Paul Desmarais, Jr., André Desmarais, Sophie Desmarais, Michel Plessis-Bélair and Guy Fortin, may be deemed to control the Reporting Persons. Decisions with respect to voting the shares of PCC held directly and indirectly by the Trust are determined by a majority of the trustees, excluding Sophie Desmarais. PCC, a corporation organized under the laws of Canada, is an international management and holding company with its principal place of business at 751 Victoria Square, Montreal (Québec), Canada H2Y 2J3. The Trust was formed under the laws of Québec and has its address at 759 Square Victoria, Montreal (Québec), Canada H2Y 2J7. Sagard Holdings Inc. (“Holdings”), a corporation organized under the laws of Canada, is a limited partner of Sagard and the sole stockholder of Manager and also may be deemed to control the Reporting Persons. Holdings has its address at 751 Victoria Square, Montreal (Québec), Canada H2Y 2J3.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    For each of the Reporting Persons, the principal business address, which also serves as the principal office, is 280 Park Avenue, 3rd Floor West, New York, NY 10017.

     

    Item 2(c).Citizenship:

     

    All Reporting Persons are organized under the laws of the state of Delaware.

     

    Item 2(d).Title of Class of Securities:

     

    Common stock, $0.0001 par value (the “Shares”)

     

    Item 2(e).CUSIP Number:

     

    47010C409

     

    Item 3.If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not applicable.

     

     

     

    CUSIP NO. 47010C40913GPage 7 of 8 Pages

     

    Item 4.Ownership:

     

    The information in Items 1 and 5 through 11 on each of the cover pages of this Amendment is hereby incorporated by reference. The filing of this Amendment represents the final amendment to the Schedule 13G and constitutes an exit filing for the Reporting Persons.

     

    The filing of this Amendment shall not be construed as an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended, the beneficial owner of the shares reported herein. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its interest therein.

     

    In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the “Release”) this filing reflects the securities beneficially owned by the Reporting Persons and PCC. The filing does not reflect securities beneficially owned, if any, by any subsidiaries of PCC whose ownership of securities is disaggregated from that of PCC in accordance with the Release.

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person:

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

     

    Not applicable

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group:

     

    Not applicable

     

    Item 10.Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP NO. 47010C40913GPage 8 of 8 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 11, 2021

     

     

      SAGARD CAPITAL PARTNERS, L.P.
         
      By: Sagard Capital Partners GP, Inc., its general partner
         
         
      By: /s/ Samuel Robinson
      Name: Samuel Robinson
      Title: President
         
      SAGARD CAPITAL PARTNERS GP, INC.
         
         
      By: /s/ Samuel Robinson
      Name: Samuel Robinson
      Title: President
         
      SAGARD CAPITAL PARTNERS MANAGEMENT CORP.
         
         
      By: /s/ Samuel Robinson
      Name: Samuel Robinson
      Title: President

     

     

    Get the next $JAGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JAGX

    DatePrice TargetRatingAnalyst
    7/7/2021$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $JAGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Micek John

      4 - Jaguar Health, Inc. (0001585608) (Issuer)

      4/2/25 8:10:19 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Siegel Jonathan B.

      4 - Jaguar Health, Inc. (0001585608) (Issuer)

      4/2/25 8:10:08 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO and President Conte Lisa A

      4 - Jaguar Health, Inc. (0001585608) (Issuer)

      4/2/25 8:10:06 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAGX
    Financials

    Live finance-specific insights

    See more
    • Jaguar Health Reports 2020 Financial Results and Business Updates

      Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020. 2020 Company Financial Results: Mytesi® Net Product Revenue: 2020 Mytesi net sales were approximately $9.3 million, and Mytesi gross (non-GAAP) sales were approximately $20.4 million, an increase of 64% and 148%, respectively, year over year. In 2020, the Company's animal product research and development efforts were intentionally minimal, and Jaguar's animal-related sales were also minimal.

      3/31/21 4:15:00 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Jaguar Health Appoints Industry Veteran to Head Sales for Company's Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

      FDA-approved Gelclair® is company's third commercialized prescription productSusan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals."Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets. We ar

      9/10/24 10:00:00 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

      Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine Miller Collis to the role of Senior Vice President of Growth Strategy."Cathy Collis was instrumental in bringing about the Gelclair in-license agreement. She is a results-oriented commercial leader with more than 25 years of experience in the biopharmaceutical industry, and

      4/18/24 8:30:00 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International

      Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S.Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium priceSAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International. A European pharmaceutical industry leader and entrepreneur with more than 35 years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, Dr

      4/2/24 8:30:00 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

      MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

      3/26/25 7:00:00 AM ET
      $AEMD
      $ASPI
      $ATCH
      $BNRG
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

      MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected]. For updates, follow us on Twitter. Day 1March 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go

      3/25/25 7:00:00 AM ET
      $AEMD
      $ASPI
      $ATCH
      $BNRG
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

      MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt

      2/19/25 6:00:00 AM ET
      $AEMD
      $ASPI
      $BDRX
      $BENF
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials

    $JAGX
    SEC Filings

    See more
    • Jaguar Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Jaguar Health, Inc. (0001585608) (Filer)

      5/15/25 4:00:32 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Jaguar Health Inc.

      10-Q - Jaguar Health, Inc. (0001585608) (Filer)

      5/15/25 2:00:35 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jaguar Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Jaguar Health, Inc. (0001585608) (Filer)

      5/9/25 6:04:56 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Jaguar Health Inc.

      SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)

      7/22/24 4:10:52 PM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jaguar Health Inc. (Amendment)

      SC 13G/A - Jaguar Health, Inc. (0001585608) (Subject)

      6/10/24 11:26:28 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Jaguar Health Inc.

      SC 13G - Jaguar Health, Inc. (0001585608) (Subject)

      12/29/23 11:09:37 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Jaguar Health with a new price target

      Cantor Fitzgerald initiated coverage of Jaguar Health with a rating of Overweight and set a new price target of $5.00

      7/7/21 6:37:12 AM ET
      $JAGX
      Biotechnology: Pharmaceutical Preparations
      Health Care